All You Need to Know About Trodelvy and Its Therapeutic Advancements

In the landscape of oncology, advancements in targeted therapies continue to reshape the way we approach and treat various types of cancer. One such groundbreaking therapeutic drug is Trodelvy (sacituzumab govitecan-hziy), a novel antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer (mTNBC), hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and metastatic urothelial cancer (mUC).

Approved by the FDA, Trodelvy offers hope to patients facing limited treatment options, demonstrating promising efficacy and tolerability in clinical trials.

Understanding Trodelvy:

Trodelvy is a first-in-class antibody-drug conjugate (ADC) designed to selectively target and deliver chemotherapy to cancer cells expressing the Trop-2 receptor. Trop-2 is overexpressed in a variety of solid tumors, including triple-negative breast cancer, HR-positive/HER2-negative breast cancer, and urothelial cancer, making it an attractive target for therapy. The medicinal product is supplied for injection: 180 mg lyophilized powder in single-dose vials for reconstitution for intravenous use.

Indications for Use:

Trodelvy 180 mgs indicated for the treatment of:

• Metastatic Triple-Negative Breast Cancer (mTNBC): This therapeutic drug is approved for patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least two prior systemic therapies for metastatic disease.
• HR-positive/HER2-negative Metastatic Breast Cancer: The medicine is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) in patients who have received two or more prior systemic therapies.
• Metastatic Urothelial Cancer (mUC): Trodelvy is also approved for patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

Dosage and Administration:

Trodelvy is administered intravenously under the supervision of a healthcare professional (HCP). The recommended dosage and treatment regimen may vary depending on the type of cancer being treated and the patient's individual characteristics.

Trodelvy is typically administered at a recommended dosage of 10 mg/kg via intravenous infusion once weekly, specifically on Days 1 and 8 within a 21-day treatment cycle. Treatment should be continued until disease progression or if any adverse reactions become unacceptable. It's essential not to exceed the recommended dosage of 10 mg/kg. Close monitoring for potential adverse reactions is essential during treatment with Trodelvy.

How Trodelvy Works:

Trodelvy utilizes a two-part mechanism of action to target and destroy cancer cells:

Targeted Delivery: The monoclonal antibody component of Trodelvy binds specifically to the Trop-2 receptor, which is overexpressed on the surface of cancer cells. This targeting mechanism allows Trodelvy to selectively deliver the attached chemotherapy payload to cancer cells while sparing healthy tissues.

Chemotherapy Payload: Once bound to the Trop-2 receptor, Trodelvy is internalized by the cancer cell, releasing its payload of the chemotherapy drug, SN-38. SN-38 is a potent inhibitor of topoisomerase I, an enzyme essential for DNA replication and cell division. By inhibiting topoisomerase I, SN-38 induces DNA damage and ultimately leads to cancer cell death.

Clinical Efficacy:

Clinical trials evaluating Trodelvy have demonstrated promising results in patients with metastatic triple-negative breast cancer and metastatic urothelial cancer. In a pivotal Phase 3 trial in mTNBC, Trodelvy significantly prolonged progression-free survival and overall survival compared to standard chemotherapy. Similarly, in a Phase 2 trial in mUC, Trodelvy showed durable responses and favorable survival outcomes in patients who had previously received platinum-based chemotherapy and immunotherapy.

Side Effects:

While Trodelvy offers significant therapeutic benefits, it can also cause side effects. Common side effects associated with Trodelvy may include:

• Neutropenia: Treatment with this medication can cause a decrease in white blood cell counts, specifically neutrophils, which can increase the risk of infection.
• Diarrhea: Gastrointestinal symptoms such as diarrhea may occur and should be managed promptly to prevent dehydration.
• Nausea and Vomiting: Some patients may experience nausea and vomiting during treatment with Trodelvy.
• Fatigue: Fatigue or weakness may occur as a result of treatment.

It is essential for patients to communicate any side effects or symptoms to their healthcare provider promptly.

Precautions and Considerations:

While Trodelvy offers significant therapeutic benefits, it is essential to consider precautions and potential risks associated with its use. Patients receiving Trodelvy should be monitored closely for adverse reactions, including:

• Hepatotoxicity: Trodelvy can cause liver damage, as indicated by elevated liver enzymes. Liver function tests should be performed regularly, and patients with pre-existing liver conditions should be closely monitored.
• Interstitial Lung Disease (ILD): ILD, including pneumonitis, can occur with Trodelvy treatment. Patients should report any new or worsening respiratory symptoms, such as cough or difficulty breathing, to their healthcare provider promptly.
• Pregnancy and Breastfeeding: Trodelvy can harm an unborn baby and should not be used during pregnancy. Women of childbearing age should use effective contraception during treatment and avoid breastfeeding.

It is crucial for healthcare providers to assess patients' medical history and closely monitor for potential complications during Trodelvy treatment. Patients should be educated about the importance of reporting any adverse reactions or symptoms to their healthcare provider promptly. By carefully considering precautions and taking appropriate measures, patients and healthcare providers can maximize the benefits of Trodelvy while minimizing risks.

Cost of Trodelvy:

At present, Trodelvy (sacituzumab govitecan) is not currently available in India. However, it's important to note that prices can fluctuate based on variables such as dosage and treatment duration. For the most accurate and current information regarding the cost of Trodelvy in India, Patients, Doctors, and Hospitals are encouraged to reach out to Indian Pharma Network (IPN) via Call/WhatsApp: +91 9310090915.

Conclusion:

Trodelvy represents a significant advancement in the treatment of breast cancer and urothelial cancer, offering a targeted and effective therapy for patients who have progressed on standard treatments. By understanding the indications, mechanism of action, clinical efficacy, and potential side effects associated with Trodelvy, patients and healthcare providers can make informed decisions about treatment options and optimize patient outcomes. Continued research and clinical trials will further elucidate the role of Trodelvy in the evolving landscape of cancer therapy.

Sources  - https://trodelvy.tumblr.com/post/749458531187556352/all-you-need-to-know-about-trodelvy-and-its

Blincyto: Revolutionizing Leukemia Treatment

 In the realm of oncology, advancements in cancer treatment continue to redefine possibilities and offer hope to patients and their families. Among these groundbreaking therapies is Blincyto (blinatumomab), a novel medication that has revolutionized the management of certain types of leukemia. 

Understanding Blincyto:

Blincyto is a bispecific T-cell engager (BiTE) antibody construct designed to harness the body's immune system to fight cancer. By simultaneously binding to CD19 on B cells and CD3 on T cells, Blincyto activates T cells to recognize and eliminate CD19-positive cancer cells. The drug is supplied for injection: 35 mcg of lyophilized powder in a single-dose vial for reconstitution for intravenous use.

Indications for Use:

Blincyto 35 mcg is indicated for the treatment of:

• B-cell Precursor Acute Lymphoblastic Leukemia (ALL): Blincyto is approved for the treatment of Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor ALL in adults and children.
• Minimal Residual Disease (MRD)-Positive B-cell Precursor ALL: Blincyto is also approved for the treatment of MRD-positive B-cell precursor ALL, a condition where small numbers of cancer cells remain detectable in the body after initial treatment.

How Blincyto Works:

Blincyto works by facilitating direct interaction between T cells and cancer cells, leading to the activation and proliferation of T cells and subsequent destruction of cancer cells. This mechanism of action differs from traditional chemotherapy and targeted therapies, making Blincyto a unique and innovative treatment option for certain types of leukemia.

Dosage and Administration:

Blincyto is administered intravenously via continuous infusion over a specified treatment cycle. The dosage and treatment schedule may vary based on factors such as the patient's age, weight, and overall health status. Healthcare providers closely monitor patients during treatment to assess response and manage potential side effects.

Side Effects:

While Blincyto offers significant therapeutic benefits, it can also cause side effects. Common side effects associated with Blincyto may include:

• Cytokine Release Syndrome (CRS): CRS is a systemic inflammatory response that can occur shortly after Blincyto infusion and may manifest as fever, chills, nausea, and fatigue.
• Neurological Toxicities: Some patients may experience neurological side effects such as headache, confusion, seizures, or speech disturbances.
• Infections: Blincyto treatment may increase the risk of infections due to decreased immune function.

Precautions and Considerations:

Before initiating treatment with Blincyto, healthcare providers assess patients' medical history and conduct appropriate tests to determine eligibility and monitor for potential complications. Additionally, patients should be educated about the following precautions:

• Monitoring and Management: Patients receiving Blincyto require close monitoring for potential side effects and complications. Healthcare providers may intervene promptly to manage adverse reactions and optimize treatment outcomes.
• Pregnancy and Breastfeeding: Blincyto may cause harm to unborn babies and should not be used during pregnancy. Patients of reproductive age should use effective contraception during treatment and avoid breastfeeding.

Cost of Blincyto (blinatumomab):

The cost of Blincyto in India can vary depending on factors such as dosage strength, and treatment duration. As a novel and targeted therapy for certain types of leukemia, Blincyto may be priced higher compared to conventional chemotherapy. 

For the best price on Blincyto and other medications, Patients, Doctors, and Hospitals are advised to 

contact Indian Pharma Network via Call/WhatsApp: +91 9310090915 or TOLL-FREE: 1800-889-1064. Unlock affordable healthcare solutions today.

Conclusion:

Blincyto represents a significant advancement in the treatment of certain types of leukemia, offering a targeted approach to therapy with the potential for improved outcomes and quality of life for patients. However, it is essential for patients to work closely with their healthcare providers to ensure safe and effective treatment. By understanding the indications, mechanism of action, side effects, and precautions associated with Blincyto, patients and healthcare providers can make informed decisions about treatment options and maximize the benefits of this innovative therapy.

Reference:

https://www.blincyto.com/

Source - https://blincyto.tumblr.com/post/749824871299776512/blincyto-revolutionizing-leukemia

Advancements in Rett Syndrome Diagnosis: Insights from India

 Rett Syndrome is a rare genetic disorder primarily affecting females, characterized by severe impairments in cognitive, motor, and communication abilities. With its prevalence estimated at 1 in 10,000 to 15,000 females worldwide, Rett Syndrome poses significant challenges for diagnosis and management. 

Advancements in Diagnosis:

Despite these challenges, India has witnessed notable progress in Rett Syndrome diagnosis in recent years. One significant advancement is the adoption of genetic testing technologies, such as next-generation sequencing (NGS), which allows for more accurate and timely diagnosis by identifying specific genetic mutations associated with Rett Syndrome. 

Collaborative Efforts and Research Initiatives:

Collaboration between healthcare institutions, advocacy groups, and research organizations has played a crucial role in advancing Rett Syndrome diagnosis in India. Multidisciplinary teams comprising geneticists, paediatricians, neurologists, and allied healthcare professionals work together to facilitate early identification and intervention for affected individuals. 

The Role of Telemedicine:

Telemedicine has emerged as a valuable tool in overcoming barriers to Rett Syndrome diagnosis, particularly in remote or underserved regions of India. Virtual consultations enable healthcare providers to reach patients in distant areas, conduct assessments, and provide guidance on diagnostic evaluation and management. By leveraging telemedicine platforms, experts can extend their expertise to areas with limited access to specialized care, ultimately improving outcomes for individuals with Rett Syndrome.

While diagnosing Rett Syndrome in India remains a complex endeavour, recent advancements in medical technology, increased awareness, and collaborative efforts have contributed to significant progress. By continuing to prioritize early detection, genetic testing, and multidisciplinary care, India can further enhance the diagnostic landscape for Rett Syndrome, ultimately improving the lives of affected individuals and their families.

 Written By- Akanksha Singh 

 Reviewed By- Dr Priyanka S Wadhwa 

#RettSyndrome #IndianResearch #NeurodevelopmentalDisorders # #EarlyDiagnosis #PediatricNeurology #HopeForRettSyndrome #IkrisPharmaNetwork

FDA Greenlights Trastuzumab Deruxtecan for Broad Use in HER2-Positive Cancers

 In a groundbreaking move, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to trastuzumab deruxtecan (Enhertu) for the treatment of any advanced solid tumor expressing high levels of the HER2 protein. This revolutionary decision marks the first time a cancer therapy of its kind, an antibody-drug conjugate, has been approved in a "tumor agnostic" manner, paving the way for a paradigm shift in cancer treatment.

Trastuzumab deruxtecan, developed by AstraZeneca and Daiichi Sankyo, is a targeted therapy that combines the targeted antibody trastuzumab (Herceptin) with the potent chemotherapy drug deruxtecan. Trastuzumab acts as a delivery vehicle, guiding the drug to cancer cells overexpressing HER2 on their surface. Once inside the cell, the cytotoxic payload, deruxtecan, is released, effectively killing the cancer cells.

The FDA's accelerated approval was based on data from three mid-stage clinical trials involving patients with advanced HER2-positive cancers, including lung, colorectal, and various other solid tumors. The results demonstrated remarkable tumor responses and durable outcomes across multiple cancer types.

In the pan-tumor trial, over half of the patients with the highest HER2 expression levels (IHC3+) experienced tumor shrinkage, with many responses lasting for 20 months or more. Notably, the most impressive responses were observed in patients with gynecologic cancers, such as endometrial and cervical cancers, with response rates exceeding 75% and some responses lasting for over a year.

"The strong and long-lasting tumor responses in people with gynecologic cancers are very exciting," said Funda Meric-Bernstam, M.D., the lead investigator of one of the trials at the University of Texas MD Anderson Cancer Center. "Based on the evidence, I expect there will be substantial uptake of trastuzumab deruxtecan among oncologists."

While the drug has shown compelling activity across various cancer types, it is essential to consider its potential side effects, particularly interstitial lung disease (ILD), a serious lung inflammation that has led to fatalities in some patients. Oncologists will need to carefully evaluate the risk-benefit ratio and closely monitor patients for early signs of ILD.

"Not all oncologists may be familiar with interstitial lung disease or pneumonitis, but it's an important adverse event to watch out for," Dr. Meric-Bernstam cautioned. "It's crucial for oncologists to take steps to catch it early and manage it effectively."

This approval represents a significant milestone in cancer treatment, offering a new option for patients with HER2-positive solid tumors where effective therapies are urgently needed. Ezra Cohen, M.D., a specialist in salivary gland cancer at the University of California San Diego Moores Cancer Center, highlighted the impact of this approval, stating, "For a difficult-to-treat cancer like salivary gland cancer, having an effective new treatment for many patients is a major advance."

As the field of oncology continues to evolve, trastuzumab deruxtecan's broad approval marks a pivotal step toward more personalized and targeted cancer care, offering renewed hope to patients with HER2-positive solid tumors.

References:

https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-enhertu-her2-positive-solid-tumors 

Buy Paxlovid (Nirmatrelvir & Ritonavir) in india

 Paxlovid (Nirmatrelvir & Ritonavir)

Drug Name: Paxlovid 

Generic Name: Nirmatrelvir & Ritonavir

Dosage Forms & Strengths: Nirmatrelvir 150 mg and ritonavir 100 mg tablets

Manufactured by: Pfizer Inc

Medicinal Uses

• PAXLOVID, which consists of ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, and nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro: also known as 3CLpro or nsp5 protease) inhibitor, is recommended for the treatment of mild-to-moderate COVID-19 in adults who are at high risk of progressing to severe COVID-19, which may require hospitalisation or even result in death.

Recommended Dosage:

Begin PAXLOVID treatment promptly after a COVID-19 diagnosis, within 5 days of symptom onset.

Take 300 mg nirmatrelvir (two 150 mg tablets) and 100 mg ritonavir (one 100 mg tablet) together, twice daily for 5 days.

For moderate kidney issues, take 150 mg nirmatrelvir (one 150 mg tablet) and 100 mg ritonavir (one 100 mg tablet) together, twice daily for 5 days.

Warnings and Precautions

• Be cautious of potential severe drug interactions; review all medications before starting PAXLOVID.
• Discontinue immediately if significant allergic reactions like anaphylaxis occur.
• Liver issues such as elevated enzymes or jaundice have been reported in some cases using ritonavir.
• Using PAXLOVID might result in HIV-1 resistance for those with uncontrolled or undiagnosed HIV-1 infection.

Documentation & Availability in India:

If you are considering the import of Paxlovid (Nirmatrelvir & Ritonavir) to India, please be aware that Paxlovid can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

• Required Documentation for Import:
• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Paxlovid (Nirmatrelvir & Ritonavir) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Elahere in India: 

Paxlovid (Nirmatrelvir & Ritonavir) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Paxlovid can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Paxlovid (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: Indian Pharma Network is proficient in sourcing Paxlovid (Nirmatrelvir & Ritonavir) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ’s

What is Paxlovid used for?

Paxlovid is utilized to treat mild-to-moderate cases of COVID-19 in adults who are at a high risk of developing severe illness or being hospitalized due to the virus.

How should Paxlovid be taken?

The recommended dosage is 300 mg of nirmatrelvir (two 150 mg tablets) along with 100 mg of ritonavir (one 100 mg tablet), taken together twice daily for 5 days, initiated within 5 days of experiencing COVID-19 symptoms.

Are there any precautions I should be aware of before taking Paxlovid?

Yes, it's crucial to review all medications with your healthcare provider before starting Paxlovid to avoid severe drug interactions. Additionally, discontinuation is necessary if significant allergic reactions occur.

Can Paxlovid cause any liver-related issues?

Some individuals using ritonavir, an element of Paxlovid, have experienced elevated liver enzymes or jaundice. Monitoring liver function may be recommended during treatment.

Who should avoid taking Paxlovid?

Paxlovid is not advised for individuals with a history of severe hypersensitivity reactions to its components or those taking specific medications susceptible to interactions with ritonavir.

Is Paxlovid FDA approved?

Yes

Arcalyst (Rilonacept)

• Medicine Name- Arcalyst 
• API- Rilonacept
• Strength- For injection: 220 mg of lyophilized powder in a single-dose vial for reconstitution
• Manufactured by- Kiniksa

Medicinal Uses

The interleukin-1 blocker ARCALYST (rilonacept) is prescribed for the following conditions in adults and children 12 years of age and older: 

Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).

Sustaining the remission of DIRA (Deficiency of Interleukin-1 Receptor Antagonist) in patients aged 10 years or older and in adults.

Treating adults and children 12 years of age and older for recurrent pericarditis (RP) and lowering their chance of recurrence

Recommended Dosage

• Administration:
• Given as a subcutaneous injection.
• For Conditions like CAPS, FCAS, MWS, and RP:

Adults:

• Loading Dose: 320 mg, two injections of 160 mg each.
• Maintenance Dose: 160 mg once weekly.
• Pediatric Patients (12 to 17 years):
• Loading Dose: 4.4 mg/kg (up to 320 mg), one or two injections.
• Maintenance Dose: 2.2 mg/kg (up to 160 mg) once weekly.

For DIRA:

Adults and Pediatric Patients (10 kg or more):

Dose: 4.4 mg/kg (up to 320 mg), one or two injections once weekly.

Patients should receive these injections as directed by their healthcare provider based on their age and specific condition.

Warning and Precautions:

Severe Infections: Patients using ARCALYST have reportedly experienced serious, sometimes fatal infections. In patients with ongoing or persistent infections, do not start ARCALYST medication. In the event that a patient gets a serious infection, stop treatment. 

Hypersensitivity Reactions: Stop giving ARCALYST and start the proper treatment if a hypersensitivity reaction happens. 

Vaccinations: Steer clear of live shots. As per current guidelines, update recommended vaccines prior to starting therapy.

Documentation & Availability in India:

If you are considering the import of Arcalyst (Rilonacept) to India, please be aware that Arcalyst can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Arcalyst (Rilonacept) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Arcalyst (Rilonacept)  in India: 

Arcalyst (Rilonacept) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Arcalyst (Rilonacept) can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Arcalyst (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: 

Indian Pharma Network is proficient in sourcing Arcalyst (Rilonacept) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ's

What is the medicine ARCALYST used for?

ARCALYST (Rilonacept) is an interleukin-1 blocker prescribed for Cryopyrin-Associated Periodic Syndromes (CAPS), sustaining remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA), and treating recurrent pericarditis (RP) in adults and children 12 years and older.

What is the recommended dosage for ARCALYST?

The dosage varies for different conditions. For CAPS, FCAS, MWS, and RP, adults usually start with a loading dose of 320 mg, followed by a maintenance dose of 160 mg weekly. Pediatric patients follow weight-based dosing.

How is ARCALYST administered?

ARCALYST is administered as a subcutaneous injection.

Are there any warnings or precautions for ARCALYST use?

Yes, severe infections have been reported, and patients with ongoing infections should avoid starting ARCALYST. Hypersensitivity reactions may occur, and live vaccinations should be avoided during therapy.

What precautions are needed for the import of ARCALYST to India?

Import requires a valid prescription, diagnostic reports, and government-issued ID for the patient. An import permit, if applicable, is essential.

How can ARCALYST be ordered in India?

To order, a valid prescription and import permit are needed. The order will be confirmed upon receipt of these documents.

Is ARCALYST available in India?

Yes, ARCALYST is available in India through Indian Pharma Network (IPN), ensuring compliance with legal requirements and facilitating efficient delivery.

Orenitram (Treprostinil) price in india

• Medicine Name- Orenitram
• API- Treprostinil
• Strength- Extended-Release Tablets: 0.125 mg, 0.25 mg, 1 mg, 2.5 mg and 5 mg. 
• Manufactured by- United Therapeutics Corp.

Medicinal Uses:

A prostacyclin mimetic called orenitram is prescribed by the World Health Organization (WHO Group 1) to treat pulmonary arterial hypertension (PAH).

To enhance exercise capacity and postpone the advancement of the disease. The majority of patients with WHO functional class II–III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH linked to connective tissue disease (26%), respectively, were included in the studies that shown efficacy.

Recommended Dosage

• Administration Instructions:
• Take Orenitram with food.
• Swallow the tablets whole; do not crush or break them.

Initial Dosing:

Start with a dose of 0.125 mg three times a day (TID) or 0.25 mg twice a day (BID).

Titration:

• Adjust the dose by 0.125 mg TID or 0.25 mg or 0.5 mg BID.
• Titrate not more frequently than every 3 to 4 days, depending on tolerance.

Transition from IV or SC Remodulin®:

If switching from intravenous (IV) or subcutaneous (SC) Remodulin, increase the Orenitram dose while simultaneously decreasing the IV/SC infusion rate.

Mild Hepatic Impairment (Child Pugh Class A):

• Initiate at 0.125 mg BID.
• Increment at 0.125 mg BID not more frequently than every 3 to 4 days.

Moderate Hepatic Impairment:

Avoid using Orenitram in patients with moderate hepatic impairment.

Note: Patients should follow these instructions carefully, and any adjustments to the medication should be made under the guidance of their healthcare provider.

Warning and Precautions:

• Don't stop taking medication suddenly. (2.5, 5.1)
• Orenitram pills may become trapped in a diverticulum in people suffering from diverticulosis.

Documentation & Availability in India:

If you are considering the import of Orenitram (Treprostinil) to India, please be aware that Orenitram can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Orenitram (Treprostinil) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Orenitram (Treprostinil) in India: 

Orenitram (Treprostinil)  is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Orenitram (Treprostinil)  can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Orenitram (Treprostinil)

(prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: 

Indian Pharma Network is proficient in sourcing Orenitram (Treprostinil) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ's

What does a treprostinil injection indicate?

The injection of treprostinil is used to treat pulmonary arterial hypertension symptoms. This hypertension affects the major blood vessel that supplies the lungs with blood from the ventricle, the right side of the heart.

What kind of medication is treprostinil?

Treprostinil belongs to a group of drugs known as platelet-aggregation inhibitors and vasodilators. It improves blood flow by relaxing blood vessels, notably those in the lungs.

Which treprostinil formulations are available?

There are three different ways to take treprostinil: as an inhalation, subcutaneous, or intravenous solution. For PAH patients, each formulation is helpful.

What is the treprostinil brand name?

Treprostinil is a vasodilator used to treat pulmonary arterial hypertension. It is marketed under the names Tyvaso for inhalation, Orenitram for oral usage, and Remodulin for infusion.

What is treprostinil's bioavailability?

Treprostinil has an oral bioavailability of 17%, and four to six hours after oral administration, the medication concentration reaches its maximum value. Food has an impact on treprostinil's oral absorption.